PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 11, 2013, Pages 4339-4344

  Iwanami, Akio ^a   Gini, Beatrice ^b,c   Zanca, Ciro ^b   Matsutani, Tomoo ^b   Assuncao, Alvaro ^d   Nael, Ali ^e   Dang, Julie ^f   Yang, Huijun ^b   Zhu, Shaojun ^g   Kohyama, Jun ^g   Kitabayashi, Issay ^h   Cavenee, Webster K ^b,i   Cloughesy, Timothy F ^g   Furnari, Frank B ^b,i   Nakamura, Masaya ^a   Toyam, Yoshiaki ^a   Okano, Hideyuki ^a   Mischel, Paul S ^b,i  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Glioma; MTORC1

Indexed keywords

ARSENIC TRIOXIDE; ERLOTINIB; MAMMALIAN TARGET OF RAPAMYCIN;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG TARGETING; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; MALE; MICE; NUCLEAR PROTEINS; OXIDES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84875009534     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217602110     Document Type: Article

References (37)

1. Furnari FB, et al. (2007) Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21(21):2683-2710.
2. Wen PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359(5):492-507.
3. Anonymous; Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455(7216):1061-1068.
4. Parsons DW, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807-1812.
5. Yecies JL, Manning BD (2011) Transcriptional control of cellular metabolism by mTOR signaling. Cancer Res 71(8):2815-2820.
6. Cloughesy TF, et al. (2008) Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5(1):e8.
7. Tanaka K, et al. (2011) Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov 1(6):524-538.
8. Bernardi R, Pandolfi PP (2003) Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22(56):9048-9057.
9. Bernardi R, Pandolfi PP (2007) Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nat Rev Mol Cell Biol 8(12):1006-1016.
10. Andre C, et al. (1996) The PML and PML/RARalpha domains: From autoimmunity to molecular oncology and from retinoic acid to arsenic. Exp Cell Res 229(2):253-260.
11. Chen GQ, et al. (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PMLRAR alpha/PML proteins. Blood 88(3):1052-1061.
12. Gurrieri C, et al. (2004) Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96(4):269-279.
13. Ito K, et al. (2008) PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453(7198):1072-1078.
14. Trotman LC, et al. (2006) Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441(7092):523-527.
15. Bernardi R, et al. (2004) PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6(7):665-672.
16. Vallian S, et al. (1997) Transcriptional repression by the promyelocytic leukemia protein, PML. Exp Cell Res 237(2):371-382.
17. Guo D, et al. (2009) EGFR signaling through an Akt-SREBP-1-dependent, rapamycinresistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal 2(101): ra82.
18. Lu KV, et al. (2009) Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res 69(17):6889-6898.
19. Aronson SM (1994) Arsenic and old myths. R I Med 77(7):233-234.
20. Mathews V, et al. (2006) Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: Durable remissions with minimal toxicity. Blood 107(7):2627-2632.
21. Soignet SL, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339(19):1341-1348.
22. Lallemand-Breitenbach V, et al. (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193(12):1361-1371.
23. de Thé H, Chen Z (2010) Acute promyelocytic leukaemia: Novel insights into the mechanisms of cure. Nat Rev Cancer 10(11):775-783.
24. Lallemand-Breitenbach V, Zhu J, Chen Z, de Thé H (2012) Curing APL through PML/RARA degradation by As2O3. Trends Mol Med 18(1):36-42.
25. Zhao S, Tsuchida T, Kawakami K, Shi C, Kawamoto K (2002) Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 21(1):49-55.
26. Mellinghoff IK, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353(19):2012-2024.
27. Gambacorta M, et al. (1996) Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 149(6): 2023-2035.
28. Bernardi R, et al. (2011) Pml represses tumour progression through inhibition of mTOR. EMBO Mol Med 3(5):249-257.
29. Scaglioni PP, et al. (2012) Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence. EMBO Mol Med 4(7):594-602.
30. Ito K, et al. (2012) A PML-PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 18(9):1350-1358.
31. Carracedo A, et al. (2012) A metabolic prosurvival role for PML in breast cancer. J Clin Invest 122(9):3088-3100.
32. Cvrljevic AN, et al. (2011) Activation of Src induces mitochondrial localisation of de2-7EGFR (EGFRvIII) in glioma cells: Implications for glucose metabolism. J Cell Sci 124(Pt 17):2938-2950.
33. Wang MY, et al. (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTENintact glioblastoma cells. Cancer Res 66(16):7864-7869.
34. Zhang XW, et al. (2010) Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML. Science 328(5975):240-243.
35. Grimm SA, et al. (2012) Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. J Neurooncol 110(2):237-243.
36. Geschwind DH, et al. (2001) A genetic analysis of neural progenitor differentiation. Neuron 29(2):325-339.
37. Nguyen LA, et al. (2005) Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 105(1):292-300.